| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg |
| ln Vitro |
Fosmanogepix (APX001) has a minimum effective dose of 0.008-0.25 μg/ml to suppress the development of Aspergillus fumigatus, Candida albicans, Clostridium neoformans, and Clostridium gattii over a 40-72 hour period[1].
|
|---|---|
| ln Vivo |
Fosmanogepix (APX001) (390 mg/kg, po, three times daily) lowers burden in the Swedish cryptococcal meningitis (CM) model [1]. Fosmanogepix (APX001) (100 mg/kg, mantra)
|
| Animal Protocol |
Animal/Disease Models: CD-1 mice [1]
Doses: 100 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: The half-life of the active part APX001A was extended from 1.3 hrs (hrs (hours)) to 8.8 hrs (hrs (hours)), increasing the area under the curve (AUC) 9 times . |
| References |
[1]. Shaw KJ, et al. In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18.
[2]. Gebremariam T, et al. APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01713-18. [3]. Shaw KJ, et al. In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00523-18. |
| Molecular Formula |
C22H21N4O6P
|
|---|---|
| Molecular Weight |
468.4058
|
| Exact Mass |
468.1199
|
| CAS # |
2091769-17-2
|
| Related CAS # |
Manogepix;936339-60-5
|
| SMILES |
P(=O)([O-])(O[H])OC([H])([H])[N+]1=C([H])C([H])=C([H])C(=C1N([H])[H])C1=C([H])C(C([H])([H])C2C([H])=C([H])C(C([H])([H])OC3=C([H])C([H])=C([H])C([H])=N3)=C([H])C=2[H])=NO1
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~10.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1349 mL | 10.6744 mL | 21.3488 mL | |
| 5 mM | 0.4270 mL | 2.1349 mL | 4.2698 mL | |
| 10 mM | 0.2135 mL | 1.0674 mL | 2.1349 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
